<DOC>
	<DOC>NCT02271659</DOC>
	<brief_summary>The aim of the present phase III study is two-folded: 1) to show a superiority of external beam radiotherapy combined with a brachytherapy boost versus exclusive external beam radiotherapy and 2) to evaluate the economic impact of each treatment. The study includes 33 cancer centres, the inclusion time is of 2 years and the follow-up is of 5 years.</brief_summary>
	<brief_title>Medical and Economic Evaluation for Intermediate-risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>age between 18 and 80 years; life expectancy of greater than 10 years; prostate adenocarcinoma histologically proven; prostate cancer has to be of intermediaterisk based on at least one of the three following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7 and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status ECOG 02. the patient has to be the beneficiary of the social security system (order n° 2006477 from April 26th 2006); the signed consent form. PSA level &gt; 20; Gleason &gt; 7; clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A won't be an exclusion criterion); prostate volume &gt; 60 cc; pelvic lymph nodes involvement at dissection or imaging (ADP &gt; 1.5 cm); concurrent hormone therapy; the presence of distant metastasis (M1); history of abdominal or pelvic irradiation; history of prostate resection in the previous 6 months and/or not allowing the implantation of markers; history of uncontrolled cancer and/or treated since less than 5 years (excepting the basalcell carcinoma); urinary discomfort with an IPSS (International Prostate Symptom Score) &gt; 15 (without alphablocking); inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease; other undergoing study that may interfere with the present study; patient under legal protection measure.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>external beam radiotherapy</keyword>
	<keyword>brachytherapy boost</keyword>
	<keyword>economical evaluation</keyword>
</DOC>